Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice
Authors
Keywords
-
Journal
CURRENT OPINION IN ONCOLOGY
Volume 25, Issue 6, Pages 609-614
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2013-10-07
DOI
10.1097/cco.0000000000000016
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
- (2013) Ruth Plummer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation
- (2013) L. Biddlestone-Thorpe et al. CLINICAL CANCER RESEARCH
- Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition
- (2012) Siker Kimbung et al. CANCER LETTERS
- Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
- (2012) A. G. Patel et al. CLINICAL CANCER RESEARCH
- Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation
- (2012) E Fokas et al. Cell Death & Disease
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells
- (2011) A. Hoglund et al. CLINICAL CANCER RESEARCH
- Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR
- (2011) David W. Schoppy et al. JOURNAL OF CLINICAL INVESTIGATION
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs
- (2011) Luis I. Toledo et al. Molecular Oncology
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
- (2011) Philip M Reaper et al. Nature Chemical Biology
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
- (2011) Neil Johnson et al. NATURE MEDICINE
- Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
- (2011) Matilde Murga et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
- (2011) Luis I Toledo et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
- (2010) N. Chan et al. CANCER RESEARCH
- Homologous recombination in cancer development, treatment and development of drug resistance
- (2010) T. Helleday CARCINOGENESIS
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
- (2010) Samuel F. Bunting et al. CELL
- Preventing Nonhomologous End Joining Suppresses DNA Repair Defects of Fanconi Anemia
- (2010) Adele Adamo et al. MOLECULAR CELL
- Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate
- (2010) C. E. Strom et al. NUCLEIC ACIDS RESEARCH
- The potential role and application of PARP inhibitors in cancer treatment
- (2009) A. J. Chalmers BRITISH MEDICAL BULLETIN
- Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma
- (2009) D. N. Yarde et al. CANCER RESEARCH
- Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
- (2009) Ji Luo et al. CELL
- Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90
- (2009) F. A. Dungey et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(ADP-Ribose) Polymerase: Mechanisms and Therapeutic Potential
- (2008) Fiona A. Dungey et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- CDK targets Sae2 to control DNA-end resection and homologous recombination
- (2008) Pablo Huertas et al. NATURE
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An Oncogene-Induced DNA Damage Model for Cancer Development
- (2008) T. D. Halazonetis et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started